Literature DB >> 18045638

The number of herpes simplex virus-infected neurons and the number of viral genome copies per neuron correlate with the latent viral load in ganglia.

Yo Hoshino1, Jing Qin, Dean Follmann, Jeffrey I Cohen, Stephen E Straus.   

Abstract

The latent viral load is the most important factor that predicts reactivation rates of animals latently infected with herpes simplex virus (HSV). To estimate the latent viral load, individual latently infected mouse trigeminal ganglia were dispersed into single cell suspensions and plated into 96-well real-time PCR plates, and HSV-2 genome copies were measured. By assuming a Poisson distribution for both the number of HSV-2 infected cells per well and the number of HSV-2 genome copies per infected cell, the numbers of infected cells and mean genome copies per infected cell were determined. Both the number of HSV-2 infected cells and the mean HSV-2 genome copy per infected cell significantly correlated with the latent viral load (p<10(-4)), indicating that both factors are responsible for the increase in the latent viral load.

Entities:  

Mesh:

Year:  2007        PMID: 18045638      PMCID: PMC2288633          DOI: 10.1016/j.virol.2007.10.031

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  22 in total

1.  Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice.

Authors:  Sarat K Dalai; Lesley Pesnicak; Georgina F Miller; Stephen E Straus
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

2.  Fractionation of neurons and satellite cells from human sensory ganglia in order to study herpesvirus latency.

Authors:  Guang-Yun Cai; Lewis I Pizer; Myron J Levin
Journal:  J Virol Methods       Date:  2002-06       Impact factor: 2.014

3.  The relationship of herpes simplex virus latency associated transcript expression to genome copy number: a quantitative study using laser capture microdissection.

Authors:  Xiao-Ping Chen; Marina Mata; Mary Kelley; Joseph C Glorioso; David J Fink
Journal:  J Neurovirol       Date:  2002-06       Impact factor: 2.643

4.  Wide variations in herpes simplex virus type 1 inoculum dose and latency-associated transcript expression phenotype do not alter the establishment of latency in the rabbit eye model.

Authors:  J E O'Neil; J M Loutsch; J S Aguilar; J M Hill; E K Wagner; D C Bloom
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  Replication of herpes simplex virus type 1 within trigeminal ganglia is required for high frequency but not high viral genome copy number latency.

Authors:  R L Thompson; N M Sawtell
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons.

Authors:  T Liu; K M Khanna; B N Carriere; R L Hendricks
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Quantitation of herpes simplex virus type 1 DNA and latency-associated transcripts in rabbit trigeminal ganglia demonstrates a stable reservoir of viral nucleic acids during latency.

Authors:  J M Hill; B M Gebhardt; R Wen; A M Bouterie; H W Thompson; R J O'Callaghan; W P Halford; H E Kaufman
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

8.  Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.

Authors:  Rachna Gupta; Anna Wald; Elizabeth Krantz; Stacy Selke; Terri Warren; Mauricio Vargas-Cortes; Gerri Miller; Lawrence Corey
Journal:  J Infect Dis       Date:  2004-09-20       Impact factor: 5.226

Review 9.  Recent progress in herpes simplex virus immunobiology and vaccine research.

Authors:  David M Koelle; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

10.  CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons.

Authors:  T Liu; K M Khanna; X Chen; D J Fink; R L Hendricks
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  15 in total

1.  Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine.

Authors:  Xavier Dervillez; Chetan Gottimukkala; Khaled W Kabbara; Chelsea Nguyen; Tina Badakhshan; Sarah M Kim; Anthony B Nesburn; Steven L Wechsler; Lbachir Benmohamed
Journal:  Future Virol       Date:  2012-04-01       Impact factor: 1.831

Review 2.  Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?

Authors:  Gargi Dasgupta; Lbachir BenMohamed
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

Review 3.  The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine.

Authors:  Tiffany Kuo; Christine Wang; Tina Badakhshan; Sravya Chilukuri; Lbachir BenMohamed
Journal:  Vaccine       Date:  2014-10-16       Impact factor: 3.641

4.  Inflation and long-term maintenance of CD8 T cells responding to a latent herpesvirus depend upon establishment of latency and presence of viral antigens.

Authors:  Anna Lang; James D Brien; Janko Nikolich-Zugich
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

5.  Impairment in reactivation of a latency associated transcript (LAT)-deficient HSV-2 is not solely dependent on the latent viral load or the number of CD8(+) T cells infiltrating the ganglia.

Authors:  Yo Hoshino; Lesley Pesnicak; Stephen E Straus; Jeffrey I Cohen
Journal:  Virology       Date:  2009-03-09       Impact factor: 3.616

6.  Cell type specific accumulation of the major latency-associated transcript (LAT) of herpes simplex virus type 2 in LAT transgenic mice.

Authors:  Kening Wang; Gowtham Mahalingam; Yumi Imai; Lesley Pesnicak; Todd P Margolis; Todd T Margolis; Stephen E Straus; Jeffrey I Cohen
Journal:  Virology       Date:  2009-02-06       Impact factor: 3.616

7.  Psychological stress exacerbates primary vaginal herpes simplex virus type 1 (HSV-1) infection by impairing both innate and adaptive immune responses.

Authors:  Kathleen A Ashcraft; Robert H Bonneau
Journal:  Brain Behav Immun       Date:  2008-06-27       Impact factor: 7.217

8.  Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay.

Authors:  Junji Sashihara; Peter D Burbelo; Barbara Savoldo; Theodore C Pierson; Jeffrey I Cohen
Journal:  Virology       Date:  2009-07-07       Impact factor: 3.616

9.  Rapid host immune response and viral dynamics in herpes simplex virus-2 infection.

Authors:  Joshua T Schiffer; Lawrence Corey
Journal:  Nat Med       Date:  2013-03       Impact factor: 53.440

10.  Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers.

Authors:  Yo Hoshino; Harutaka Katano; Ping Zou; Patricia Hohman; Adriana Marques; Stephen K Tyring; Dean Follmann; Jeffrey I Cohen
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.